We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of SGLT‐2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta‐analysis and Bayesian sensitivity analysis
SGLT-2 inhibitors and flare-ups of lung disease in people with type 2 diabetes: A combined and sensitivity analysis
AI simplified
Abstract
reduced risk by 39% in patients with Type 2 diabetes.
- Seven studies with 449,530 participants were analyzed for the effects of SGLT-2 inhibitors on COPD exacerbations in individuals with Type 2 diabetes.
- The pooled analysis indicated a reduced risk of COPD exacerbations with SGLT-2 inhibitors, demonstrating a hazard ratio of 0.609.
- Bayesian analysis corroborated a 31% reduction in exacerbation risk with a hazard ratio of 0.64.
- Subgroup analyses revealed SGLT-2 inhibitors were more effective than DPP-4 inhibitors and sulfonylureas in reducing exacerbations.
- No significant reduction in severe COPD exacerbations was observed, with a hazard ratio of 0.676.
- High heterogeneity among studies was noted, but sensitivity analyses confirmed the robustness of the findings.
AI simplified
Key numbers
39%
Reduction in Risk
Pooled hazard ratio for COPD exacerbations in T2DM patients using .
0.618
Pooled Hazard Ratio vs. DPP-4 Inhibitors
Hazard ratio comparing to DPP-4 inhibitors for COPD exacerbations.
0.620
Pooled Hazard Ratio vs. Sulfonylureas
Hazard ratio comparing to sulfonylureas for COPD exacerbations.